Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

Other free copies

• Erasmus University Rotterdam (pure.eur.nl)Published version · Web page
• University of Groningen (research.rug.nl)Published version · Web page
• edepot.wur.nlAccepted manuscript · PDF
• London School of Hygiene & Tropical Medicine (researchonline.lshtm.ac.uk)Accepted manuscript · PDF
• University of the Coast (hdl.handle.net)Accepted manuscript · Web page
• Australian National University (openresearch-repository.anu.edu.au)Preprint · PDF
• The University of Melbourne (hdl.handle.net)Preprint · PDF
• open-science.canada.caPreprint · PDF
• Auckland University of Technology (openrepository.aut.ac.nz)Preprint · PDF
• University of Copenhagen (curis.ku.dk)Preprint · PDF
• LA Referencia (repositorio.ufmg.br)Preprint · PDF
• National Institutes of Health (ncbi.nlm.nih.gov)Preprint · Web page
• Monash University (research.monash.edu)Preprint · Web page
• The University of Western Australia (admin.research-repository.uwa.edu.au)Preprint · Web page
• Jagiellonian University (ruj.uj.edu.pl)Preprint · Web page
• ruj.uj.edu.plPreprint · Web page
• University of South Australia (find.library.unisa.edu.au)Preprint · Web page
• Erasmus University Rotterdam (hdl.handle.net)Preprint · Web page
• urn.kb.sePreprint · Web page
• KTH Royal Institute of Technology (urn.kb.se)Preprint · Web page
• University of Milano-Bicocca (hdl.handle.net)Preprint · Web page
• The University of Adelaide (hdl.handle.net)Preprint · Web page
• Universitat de Barcelona (hdl.handle.net)Preprint · Web page
• LA Referencia (hdl.handle.net)Preprint · Web page
• Nanyang Technological University (hdl.handle.net)Preprint · Web page
• California Digital Library (escholarship.org)Preprint · Web page
• hdl.handle.netPreprint · Web page
• Technical University of Munich (mediatum.ub.tum.de)Preprint · Web page
• hdl.handle.netPreprint · Web page
• Auckland University of Technology (hdl.handle.net)Preprint · Web page
• Australian National University (hdl.handle.net)Preprint · Web page
• hdl.handle.netPreprint · Web page
• University of Technology Sydney (hdl.handle.net)Preprint · Web page
• pure.amsterdamumc.nlPreprint · Web page
• pure.au.dkPreprint · Web page
• scopus.comPreprint · Web page
• University of Edinburgh (research.ed.ac.uk)Preprint · Web page
• Erasmus University Rotterdam (repub.eur.nl)Preprint · Web page
• University of Auckland (hdl.handle.net)Preprint · Web page
• University of Bari Aldo Moro (hdl.handle.net)Preprint · Web page
• Imperial College London (hdl.handle.net)Preprint · Web page
• Tampere University of Applied Sciences (trepo.tuni.fi)Preprint · Web page
• hdl.handle.netPreprint · Web page
• Royal Netherlands Academy of Arts and Sciences (research.vumc.nl)Preprint · Web page
• Royal Netherlands Academy of Arts and Sciences (research.wur.nl)Preprint · Web page

Abstract

BACKGROUND: Neurological disorders are increasingly recognised as major causes of death and disability worldwide. The aim of this analysis from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 is to provide the most comprehensive and up-to-date estimates of the global, regional, and national burden from neurological disorders. METHODS: We estimated prevalence, incidence, deaths, and disability-adjusted life-years (DALYs; the sum of years of life lost [YLLs] and years lived with disability [YLDs]) by age and sex for 15 neurological disorder categories (tetanus, meningitis, encephalitis, stroke, brain and other CNS cancers, traumatic brain injury, spinal cord injury, Alzheimer's disease and other dementias, Parkinson's disease, multiple sclerosis, motor neuron diseases, idiopathic epilepsy, migraine, tension-type headache, and a residual category for other less common neurological disorders) in 195 countries from 1990 to 2016. DisMod-MR 2.1, a Bayesian meta-regression tool, was the main method of estimation of prevalence and incidence, and the Cause of Death Ensemble model (CODEm) was used for mortality estimation. We quantified the contribution of 84 risks and combinations of risk to the disease estimates for the 15 neurological disorder categories using the GBD comparative risk assessment approach. FINDINGS: Globally, in 2016, neurological disorders were the leading cause of DALYs (276 million [95% UI 247-308]) and second leading cause of deaths (9·0 million [8·8-9·4]). The absolute number of deaths and DALYs from all neurological disorders combined increased (deaths by 39% [34-44] and DALYs by 15% [9-21]) whereas their age-standardised rates decreased (deaths by 28% [26-30] and DALYs by 27% [24-31]) between 1990 and 2016. The only neurological disorders that had a decrease in rates and absolute numbers of deaths and DALYs were tetanus, meningitis, and encephalitis. The four largest contributors of neurological DALYs were stroke (42·2% [38·6-46·1]), migraine (16·3% [11·7-20·8]), Alzheimer's and other dementias (10·4% [9·0-12·1]), and meningitis (7·9% [6·6-10·4]). For the combined neurological disorders, age-standardised DALY rates were significantly higher in males than in females (male-to-female ratio 1·12 [1·05-1·20]), but migraine, multiple sclerosis, and tension-type headache were more common and caused more burden in females, with male-to-female ratios of less than 0·7. The 84 risks quantified in GBD explain less than 10% of neurological disorder DALY burdens, except stroke, for which 88·8% (86·5-90·9) of DALYs are attributable to risk factors, and to a lesser extent Alzheimer's disease and other dementias (22·3% [11·8-35·1] of DALYs are risk attributable) and idiopathic epilepsy (14·1% [10·8-17·5] of DALYs are risk attributable). INTERPRETATION: Globally, the burden of neurological disorders, as measured by the absolute number of DALYs, continues to increase. As populations are growing and ageing, and the prevalence of major disabling neurological disorders steeply increases with age, governments will face increasing demand for treatment, rehabilitation, and support services for neurological disorders. The scarcity of established modifiable risks for most of the neurological burden demonstrates that new knowledge is required to develop effective prevention and treatment strategies. FUNDING: Bill & Melinda Gates Foundation.